NCT03251612View on ClinicalTrials.gov

Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

September 22, 2017

Primary Completion Date

August 23, 2021

Study Completion Date

March 21, 2022

Conditions
Colorectal Cancer Metastatic
Interventions
DRUG

Based on sensitivity analysis

"* 5FU, infusional~* Capecitabine~* Oxaliplatin (FOLFOX)~* Irinotecan (FOLFIRI)~* FOLFOXIRI (triplet)~* Bevacizumab~* Panitumumab~* Cetuximab~* Regorafenib~* Tas-102~* Ramucirumab~* Aflibercept~* Pembrolizumab~* Nivolumab~* Vinorelbine and capecitabine~* Sorafenib~* Gemcitabine and capecitabine~* Olaparib~* Epirubicin"

Trial Locations (4)

Unknown

Department of Oncology, Aalborg University Hospital, Aalborg

Department of Oncology, Rigshospitalet, Copenhagen

Departmen of Oncology, Vejle Hospital, Vejle

Universitätsklinikum Hamburg - Eppendorf, Universitäres Cancer Center Hamburg (UCCH), Hamburg

All Listed Sponsors
lead

Vejle Hospital

OTHER

NCT03251612 - Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter